Tag - SLNO

Soleno Therapeutics (NASDAQ:SLNO) updated topline results from its Phase 3 trial evaluating diazoxide choline controlled-release (DCCR) tablets for the treatment of Prader-Willi Syndrome (PWS). The randomized, double...